NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INM
Post# of 33
(Total Views: 324)
Posted On: 06/05/2019 3:56:08 PM
NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019. According to the update, “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (“AD”) patients,” is the title of the poster and talk in which Barnum will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease. “XPro1595 has been represented at the TNF Conference for more than a decade. I am often told that the support and feedback provided by TNF experts at this conference has gone a long way in shaping the enormous dataset that we enjoy with XPro1595,” Barnum stated in the news release. “I am very excited to share how these efforts have paid off and that we are days away from enrolling the first patient in our Alzheimer’s disease trial.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019. According to the update, “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (“AD”) patients,” is the title of the poster and talk in which Barnum will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease. “XPro1595 has been represented at the TNF Conference for more than a decade. I am often told that the support and feedback provided by TNF experts at this conference has gone a long way in shaping the enormous dataset that we enjoy with XPro1595,” Barnum stated in the news release. “I am very excited to share how these efforts have paid off and that we are days away from enrolling the first patient in our Alzheimer’s disease trial.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)